Overview

A Study Comparing Rapid Acting Intramuscular Olanzapine and Placebo in Agitated Patients With Schizophrenia

Status:
Completed
Trial end date:
2008-07-01
Target enrollment:
Participant gender:
Summary
The primary objectives of the study is to confirm if the efficacy of IM olanzapine in patients with schizophrenia is greater than IM placebo by comparing changes from baseline to 2 hours post first IM injection of agitation.
Phase:
Phase 3
Details
Lead Sponsor:
Eli Lilly and Company
Treatments:
Olanzapine
Polystyrene sulfonic acid